

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LifeTech Scientific Corporation

先健科技公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1302)

VOLUNTARY ANNOUNCEMENT UPDATE ON BUSINESS DEVELOPMENT OF THE COMPANY

This announcement is made by LifeTech Scientific Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide its shareholders and potential investors with information on the latest business development of the Company.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that the Group has completed the construction of its first animal laboratory (the “**Animal Laboratory**”) in Shenzhen of the People’s Republic of China (“**PRC**”).

The Group has been committed to research and development (“**R&D**”) of innovative medical devices and technology and the Group has set up R&D laboratories to support R&D of innovative medical devices and technology. Since 2012, the Group’s R&D laboratories are authorized and entitled by central, principal and municipal governments as state class, provincial class and municipal class interventional biomaterials and device related research centres or engineering laboratories as well as state postdoctorate research working stations. The Group has also been cooperating with various renowned universities, hospitals and other medical institutions in the PRC such as Peking University, Tsinghua University and Fudan University on R&D projects related to cardiovascular medical devices. As at the date of this announcement, more than 180 testing items has been recognized by China National Accreditation Service for Conformity Assessment, and the testing reports issued by our R&D laboratories have been recognized by over 70 international institutions. The Board considers that the successful construction of the Animal Laboratory is crucial to the Group’s R&D.

The newly established pre-clinical test Animal Laboratory at present has a surgery room and an interventional catheterization laboratory, can breed approximately 820 animals, for instance, rabbits, rats and some big animals such as pigs, etc at the same time. In addition, the Animal Laboratory is well-equipped with large medical equipment, such as digital subtraction angiography (DSA), optical coherence tomography (OCT), high performance liquid chromatography-tandem mass spectrometry (LC-MS/MS), high performance liquid chromatography (HPLC), micro-computed tomography (Micro-CT), scanning electronic microscopy (SEM), energy dispersive spectroscopy (EDS), blood cell analyzer and fluorescence microscopy, as well as automatic biochemical analyzers, paraffin slicing machines, cryostat microtome, paraffin embedding station, femtosecond laser hard tissue machines, automatic staining machines, anesthesia machines, to provide a full range of pre-clinical evaluation experiments for researches on orthopedics, cardiovascular devices and drug-contained medical devices.

The Animal Laboratory is the first laboratory fully-equipped for animal testing in the southern PRC and one of the very few laboratories of this kind in PRC. The Animal Laboratory is also the only laboratory in the PRC which can be used for device-implantation experiments, pathology evaluation and pharmacokinetics testing, as well as physical and chemical testing, failure analysis, packaging, sterilization and regulatory consultation and preparation of registration documents at the same time.

The Group plans to use the Animal Laboratory for testing and quality control of its products, as well as for conducting research projects with outside cardiovascular and orthopedic implantable devices manufacturers, universities, hospitals, research institutes, and biotechnology and pharmaceutical companies. It is expected that the Animal Laboratory will act as both an internal and external research platform, and provide a full range of high-quality and professional services related to research and experiment to third parties.

By Order of the Board
LifeTech Scientific Corporation
XIE Yuehui
*Chairman, Chief Executive Officer
and Executive Director*

Hong Kong, 9 November 2015

As at the date of this announcement, the Board comprises Mr. XIE Yuehui and Mr. LIU Jianxiong being executive Directors; Mr. WU Jianhui, Mr. MONAGHAN Shawn Del, Mr. JIANG Feng and Mr. CLEARY Christopher Michael being non-executive Directors; and Mr. LIANG Hsien Tse Joseph, Mr. ZHOU Gengshen and Mr. ZHOU Luming being independent non-executive Directors.